Trading update for the period ending 30 June 2022

Appointment of Vice President of Investor Relations

Appointment of Vice President of Investor Relations

Results for the 12- and 18-month periods ended 31 December 2021

Trading update for the period ended 31 December 2021

Interim results for the 6- and 12-month periods ended 30 June 2021

Abcam to acquire BioVision for $340 million

Interim results for the 6 month-period ended 31 December 2020

Abcam – Half Year Trading Update

Abcam Announces Pricing of Offering on NASDAQ